Winners Announced in Prestigious GCCA Photo Competition Which Highlights Beauty and Essential Role of Concrete Throughout World
15.2.2023 15:30:00 EET | Business Wire | Press release
A stunning image of a skateboard park in the United Arab Emirates has been named Concrete in Life Photo of the Year. It wins a top prize of $10,000 (ten thousand US dollars) in a global competition, which highlights the essential role that concrete plays around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005136/en/
Ferdz Bedana, winner Urban Concrete Professional and overall winner, Concrete in Life Photo of Year. Location Sharjah, UAE
The photo, taken by professional photographer, Ferdz Bedana, in Sharjah, was announced as the overall winner in a live Instagram broadcast, on 15th February. It was selected from more than 14,000 photos submitted by both amateur and professional photographers from every continent, in the annual competition run by the Global Cement and Concrete Association.
Thomas Guillot, GCCA Chief Executive said: “Concrete is the second most used substance on earth after water and plays a vital part in modern infrastructure and society. Through the work of the GCCA and our members, to implement our 2050 Net Zero Roadmap, we are working hard and making progress in reducing its environmental impact. These amazing photos capture the appeal of concrete design and the essential role it plays in modern life and communities everywhere.”
Entrants from around the world submitted photos across four categories: concrete infrastructure, concrete beauty and design, urban concrete, and concrete in daily life, with each section divided between professional photographers and amateurs, often with smart phones. The breadth and variety of all the entries highlight the way concrete supports life around the world, from the giant to the small form, as well as the material’s grace, beauty and crucial supporting role.
Eight category winners each receive a prize of $2,500 (two thousand, five hundred US dollars) each. As well as Ferdz Bedana’s skateboarder image, the category winners include images of a waterfall and a roller-skater race, both taken in Indonesia, a stunning city interchange in China, rice mills in Bangladesh, a university building in Mexico, a metro station in Dubai and a Mosque in Istanbul, Turkey.
Ferdz Bedana who took the overall Concrete in Life Photo of Year in Sharjah, said: “It’s a great honour to be the overall winner of the Concrete in Life 2022 competition and spread the story of how concrete is a big contribution in our life. I was interested to take a photo of this skatepark when I saw a boy enjoying playing in a substantially artistic concrete design.”
Chris George, Content Director at Digital Camera World, and one of the competition judges said about the winning photo: “This was an amazing capture, that perfectly shows the energy of skateboarding against the organic form of the manmade structure.”
Fellow judge, freelance writer and photographer Norman Miller added: “It’s a real skill to capture fast moving subject while showing mastery of framing and control of lighting.”
Thomas Guillot, GCCA Chief Executive added: “Congratulations to Ferdz Bedana and all our category winners. Check out our website to see all the shortlisted entries who were all outstanding.”
The GCCA and its member companies, which account for 80% of global cement production capacity outside of China, as well as key Chinese manufacturers, are committed to reducing and eliminating CO2 emissions through implementation of the Concrete Future - 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
Notes to editors:
Images available for media to use here .
Video of Instagram broadcast announcing winners available here .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005136/en/
Contact information
For further details, or interview requests:
Simon Thomson, Head of Media, GCCA
simon.thomson@gccassociation.org / +44 7380 972282
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
